Europe Liposome Drug Delivery Market to Reach US$ 2,160.12 Million at a CAGR of 8.2% in 2027

AI Analysis: Key Insights from the Press Release

Show Key Insights

Market Size (2019): US$ 1,164.54 Mn

Forecast Market Size (2027): US$ 2,160.12 Mn

CAGR (2020–2027): 8.2%

Primary Growth Drivers: Liposome Drug Delivery in Cancer Therapy

Key Trends: Fast regulatory approval

Growth Opportunities: Research & Development (R&D) Activities

Base Value (2019)

US$ 1,164.54 Mn

Projected (2027)

US$ 2,160.12 Mn

CAGR (2020-2027)

8.2%

liposomal amphotericin B segment by product is estimated to lead the market growth during the forecast period

According to a new market research study of “Europe Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology and Application,”The Europe liposome drug delivery market was valued at US$ 1,164.54 million in 2019 and is projected to reach US$ 2,160.12 million by 2027; it is expected to grow at a CAGR of 8.2% during the forecast period.

The growing R&D expenditure on drug delivery, growing demand for non-invasive drug delivery devices, and the development of new lipid composition for stability and optimization of drugs are the major factors propelling the growth of the Europe liposome drug delivery market during the forecast period. High costs of R&D and impact of COVID-19 pandemic are likely to restrain the growth of the market during the forecast period.

Based on the Product, the liposomal doxorubicin segment held the highest share of Europe Liposome Drug Delivery market in 2019. However, the liposomal amphotericin B segment is expected to grow at a higher CAGR during the forecast period. The governments in European countries are encouraging the acceptance and adoption of liposomal drug deliver with an aim to streamline and improvise the process of drug delivery. It also provides a premier interdisciplinary platform for researchers, practitioners, and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered in application of amniotic membrane. Companies in the liposome drug delivery market are increasing their focus on drug delivery nanosystems involving major antiviral classes and their transport across specific barriers at a cellular and intracellular level. Thus, liposomes hold promising potentials in ongoing research studies being carried out by healthcare companies for the treatment of COVID-19.

European and Developing Countries Clinical Trials Partnership (EDCTP), Europa Bio, European Federation of Biotechnology (EFB), and Celsion Corporation are among the leading companies operating in the Europe Liposome Drug Delivery market.